Genbiotech and TxCell sign a partnership agreement on the use of its technical platform.
Antibes, France March 1st. Genbiotech and TxCell announced the signing of a two years partnership agreement for the use of a part of its class B facilities for Process Development activities and to host the TxCell academy technologies transfer. The academy will be responsible for educating and training contract manufacturing and other partners on the manufacturing process of both the antigen specific and genetically modified T regulatory cell platforms of TxCell.
“The opening of the new process development and technology transfer laboratories in the facilities of Genbiotech is a great development for TxCell” said Stéphane Boissel, CEO of TxCell